Indication: Merkel Cell Carcinoma (MCC)

A Phase 2, Open-Label, Single-Arm Study of KRT-232 in Patients with p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy

Failed anti-PD-1 or anti-PDL-1 immunotherapy

Sub-indication: Patients must have failed treatment with at least one PD-1 inhibitor or PD-L1 inhibitor for MCC

Line of Therapy: 2nd line and beyond

Drug Study

Principal Investigator: Jaspreet Grewal, M.D.
Norton Cancer Institute

Sponsor: Kartos Therapeutics, Inc

Learn more at ClinicalTrials.gov

Email for more information: Derm-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.